{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:58:09Z","timestamp":1790719089380,"version":"4.1.0"},"reference-count":57,"publisher":"Portland Press Ltd.","issue":"7","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,4,1]]},"abstract":"<jats:p>Binding of 14-3-3 proteins to leucine-rich repeat protein kinase 2 (LRRK2) is known to be impaired by many Parkinson's disease (PD)-relevant mutations. Abrogation of this interaction is connected to enhanced LRRK2 kinase activity, which in turn is implicated in increased ubiquitination of LRRK2, accumulation of LRRK2 into inclusion bodies and reduction in neurite length. Hence, the interaction between 14-3-3 and LRRK2 is of significant interest as a possible drug target for the treatment of PD. However, LRRK2 possesses multiple sites that, upon phosphorylation, can bind to 14-3-3, thus rendering the interaction relatively complex. Using biochemical assays and crystal structures, we characterize the multivalent interaction between these two proteins.<\/jats:p>","DOI":"10.1042\/bcj20161078","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T01:10:53Z","timestamp":1487207453000},"page":"1273-1287","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Structural interface between LRRK2 and 14-3-3 protein"],"prefix":"10.1042","volume":"474","author":[{"given":"Loes M.","family":"Stevers","sequence":"first","affiliation":[{"name":"Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, PO Box 513, 5600 MB Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rens M.J.M.","family":"de Vries","sequence":"additional","affiliation":[{"name":"Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, PO Box 513, 5600 MB Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Doveston","sequence":"additional","affiliation":[{"name":"Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, PO Box 513, 5600 MB Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lech-Gustav","family":"Milroy","sequence":"additional","affiliation":[{"name":"Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, PO Box 513, 5600 MB Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Brunsveld","sequence":"additional","affiliation":[{"name":"Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, PO Box 513, 5600 MB Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ottmann","sequence":"additional","affiliation":[{"name":"Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, PO Box 513, 5600 MB Eindhoven, The Netherlands"},{"name":"Department of Chemistry, University of Duisburg-Essen, 45141 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2017,3,23]]},"reference":[{"key":"2021112216514588500_BCJ-2016-1078C1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/ane.12563","article-title":"The genetic background of Parkinson's disease: current progress and future prospects","volume":"134","author":"Kalinderi","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"2021112216514588500_BCJ-2016-1078C2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"key":"2021112216514588500_BCJ-2016-1078C3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease","volume":"44","author":"Pais\u00e1n-Ru\u0131\u00b4z","year":"2004","journal-title":"Neuron"},{"key":"2021112216514588500_BCJ-2016-1078C4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0140-6736(05)17829-5","article-title":"A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease","volume":"365","author":"Di Fonzo","year":"2005","journal-title":"Lancet"},{"key":"2021112216514588500_BCJ-2016-1078C5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case\u2013control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurol."},{"key":"2021112216514588500_BCJ-2016-1078C6","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1093\/hmg\/ddi376","article-title":"Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease","volume":"14","author":"Skipper","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"2021112216514588500_BCJ-2016-1078C7","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/ana.20456","article-title":"Clinical features of LRRK2-associated Parkinson's disease in central Norway","volume":"57","author":"Aasly","year":"2005","journal-title":"Ann. Neurol."},{"key":"2021112216514588500_BCJ-2016-1078C8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1471-4159.2011.07537.x","article-title":"Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition","volume":"120","author":"Doggett","year":"2012","journal-title":"J. Neurochem."},{"key":"2021112216514588500_BCJ-2016-1078C9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/jnr.23331","article-title":"Evidence that the LRRK2 ROC domain Parkinson's disease-associated mutants A1442P and R1441C exhibit increased intracellular degradation","volume":"92","author":"Greene","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"2021112216514588500_BCJ-2016-1078C10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.bbrc.2009.10.034","article-title":"I(2020)T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular degradation rate than the wild-type molecule","volume":"390","author":"Ohta","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021112216514588500_BCJ-2016-1078C11","doi-asserted-by":"publisher","first-page":"E34","DOI":"10.1073\/pnas.1312701111","article-title":"Parkinson-related LRRK2 mutation R1441C\/G\/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3","volume":"111","author":"Muda","year":"2014","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112216514588500_BCJ-2016-1078C12","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1042\/BST20120054","article-title":"Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease","volume":"40","author":"Greggio","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"2021112216514588500_BCJ-2016-1078C13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1042\/BJ20100784","article-title":"Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910\/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization","volume":"430","author":"Dzamko","year":"2010","journal-title":"Biochem. J."},{"key":"2021112216514588500_BCJ-2016-1078C14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1042\/BJ20100483","article-title":"14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization","volume":"430","author":"Nichols","year":"2010","journal-title":"Biochem. J."},{"key":"2021112216514588500_BCJ-2016-1078C15","doi-asserted-by":"publisher","first-page":"e17153","DOI":"10.1371\/journal.pone.0017153","article-title":"Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease","volume":"6","author":"Li","year":"2011","journal-title":"PLoS ONE,"},{"key":"2021112216514588500_BCJ-2016-1078C16","doi-asserted-by":"publisher","first-page":"4988","DOI":"10.1093\/hmg\/ddt346","article-title":"LRRK2 secretion in exosomes is regulated by 14-3-3","volume":"22","author":"Fraser","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"2021112216514588500_BCJ-2016-1078C17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1042\/BJ20141305","article-title":"LRRK2 dephosphorylation increases its ubiquitination","volume":"469","author":"Zhao","year":"2015","journal-title":"Biochem. J."},{"key":"2021112216514588500_BCJ-2016-1078C18","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1042\/BJ20101200","article-title":"14-3-3 proteins are promising LRRK2 interactors","volume":"430","author":"Rudenko","year":"2010","journal-title":"Biochem. J."},{"key":"2021112216514588500_BCJ-2016-1078C19","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1042\/BJ20150785","article-title":"LRRK2 and ubiquitination: implications for kinase inhibitor therapy","volume":"470","author":"Melrose","year":"2015","journal-title":"Biochem. J."},{"key":"2021112216514588500_BCJ-2016-1078C20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/hmg\/ddv453","article-title":"14-3-3 proteins regulate mutant LRRK2 kinase activity and neurite shortening","volume":"25","author":"Lavalley","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"2021112216514588500_BCJ-2016-1078C21","doi-asserted-by":"publisher","first-page":"bat085","DOI":"10.1093\/database\/bat085","article-title":"ANIA: ANnotation and integrated analysis of the 14-3-3 interactome","volume":"2014","author":"Tinti","year":"2014","journal-title":"Database (Oxford)"},{"key":"2021112216514588500_BCJ-2016-1078C22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.drudis.2015.09.012","article-title":"The role of the 14-3-3 protein family in health, disease, and drug development","volume":"21","author":"Aghazadeh","year":"2016","journal-title":"Drug Discov. Today"},{"key":"2021112216514588500_BCJ-2016-1078C23","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1096\/fj.14-265009","article-title":"Involvement of 14-3-3 in tubulin instability and impaired axon development is mediated by Tau","volume":"29","author":"Joo","year":"2015","journal-title":"FASEB J."},{"key":"2021112216514588500_BCJ-2016-1078C24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0092-8674(00)81382-3","article-title":"Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL","volume":"87","author":"Zha","year":"1996","journal-title":"Cell"},{"key":"2021112216514588500_BCJ-2016-1078C25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1242\/jcs.105817","article-title":"14-3-3 proteins interact with neurofilament protein-L and regulate dynamic assembly of neurofilaments","volume":"126","author":"Miao","year":"2013","journal-title":"J. Cell Sci."},{"key":"2021112216514588500_BCJ-2016-1078C26","doi-asserted-by":"publisher","first-page":"E1152","DOI":"10.1073\/pnas.1516631113","article-title":"Characterization and small-molecule stabilization of the multisite tandem binding between 14-3-3 and the R domain of CFTR","volume":"113","author":"Stevers","year":"2016","journal-title":"Proc. Natl Acad. Sci."},{"key":"2021112216514588500_BCJ-2016-1078C27","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1021\/cb4003464","article-title":"Stabilization of physical RAF\/14-3-3 interaction by cotylenin A as treatment strategy for RAS mutant cancers","volume":"8","author":"Molzan","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"2021112216514588500_BCJ-2016-1078C28","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1002\/anie.201310082","article-title":"Constrained peptides with target-adapted cross-links as inhibitors of a pathogenic protein\u2013protein interaction","volume":"53","author":"Glas","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2021112216514588500_BCJ-2016-1078C29","doi-asserted-by":"publisher","first-page":"15720","DOI":"10.1002\/anie.201507976","article-title":"Stabilizer-Guided inhibition of protein\u2013protein interactions","volume":"54","author":"Milroy","year":"2015","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2021112216514588500_BCJ-2016-1078C30","doi-asserted-by":"publisher","first-page":"16212","DOI":"10.1073\/pnas.1100012108","article-title":"Discovery and structural characterization of a small molecule 14-3-3 protein\u2013protein interaction inhibitor","volume":"108","author":"Zhao","year":"2011","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112216514588500_BCJ-2016-1078C31","doi-asserted-by":"publisher","first-page":"8468","DOI":"10.1039\/c3cc44612c","article-title":"Virtual screening and experimental validation reveal novel small-molecule inhibitors of 14-3-3 protein\u2013protein interactions","volume":"49","author":"Thiel","year":"2013","journal-title":"Chem. Commun. (Camb.)."},{"key":"2021112216514588500_BCJ-2016-1078C32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nchem.1570","article-title":"Molecular tweezers modulate 14-3-3 protein\u2013protein interactions","volume":"5","author":"Bier","year":"2013","journal-title":"Nat. Chem."},{"key":"2021112216514588500_BCJ-2016-1078C33","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3892\/ijo.2014.2760","article-title":"Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells","volume":"46","author":"Kasukabe","year":"2015","journal-title":"Int. J. Oncol."},{"key":"2021112216514588500_BCJ-2016-1078C34","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/hmg\/ddl471","article-title":"Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity","volume":"16","author":"West","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"2021112216514588500_BCJ-2016-1078C35","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/embor.2009.150","article-title":"Recognition of an intra-chain tandem 14-3-3 binding site within PKC\u025b","volume":"10","author":"Kostelecky","year":"2009","journal-title":"EMBO Rep."},{"key":"2021112216514588500_BCJ-2016-1078C36","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jmb.2012.08.009","article-title":"Synergistic binding of the phosphorylated S233- and S259-binding sites of C-?RAF to one 14-3-3\u03b6 dimer","volume":"423","author":"Molzan","year":"2012","journal-title":"J. Mol. Biol."},{"key":"2021112216514588500_BCJ-2016-1078C37","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/cmdc.201500484","article-title":"Small-molecule stabilization of the 14-3-3\/Gab2 protein\u2013protein interaction (PPI) interface","volume":"11","author":"Bier","year":"2016","journal-title":"ChemMedChem"},{"key":"2021112216514588500_BCJ-2016-1078C38","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.febslet.2010.02.065","article-title":"Structure of the p53 C-?terminus bound to 14-3-3: implications for stabilization of the p53 tetramer","volume":"584","author":"Schumacher","year":"2010","journal-title":"FEBS Lett."},{"key":"2021112216514588500_BCJ-2016-1078C39","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1073\/pnas.90.6.2320","article-title":"The eukaryotic host factor that activates Exoenzyme S of Pseudomonas aeruginosa is a member of the 14-3-3 protein family","volume":"90","author":"Fu","year":"1993","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112216514588500_BCJ-2016-1078C40","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/sj.emboj.7601530","article-title":"Phosphorylation-independent interaction between 14-3-3 and Exoenzyme S: from structure to pathogenesis","volume":"26","author":"Ottmann","year":"2007","journal-title":"EMBO J."},{"key":"2021112216514588500_BCJ-2016-1078C41","doi-asserted-by":"publisher","first-page":"8894","DOI":"10.1073\/pnas.1220809110","article-title":"Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface","volume":"110","author":"De Vries-van Leeuwen","year":"2013","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112216514588500_BCJ-2016-1078C42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.molcel.2005.08.032","article-title":"Molecular basis for the recognition of phosphorylated and phosphoacetylated histone h3 by 14-3-3","volume":"20","author":"Macdonald","year":"2005","journal-title":"Mol. Cell."},{"key":"2021112216514588500_BCJ-2016-1078C43","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.26075","article-title":"Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic","volume":"30","author":"West","year":"2015","journal-title":"Mov. Disord."},{"key":"2021112216514588500_BCJ-2016-1078C44","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2174\/156802661510150328223655","article-title":"Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease","volume":"15","author":"Gilligan","year":"2015","journal-title":"Curr. Top. Med. Chem."},{"key":"2021112216514588500_BCJ-2016-1078C45","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1093\/hmg\/ddr348","article-title":"LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice","volume":"20","author":"Herzig","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"Suppl. 1","key":"2021112216514588500_BCJ-2016-1078C46","first-page":"1186","article-title":"LRRK2 kinase inhibition reduces endogenous LRRK2 protein levels in vivo","volume":"15","author":"Lobbestael","year":"2015","journal-title":"Neurodegener. Dis."},{"key":"2021112216514588500_BCJ-2016-1078C47","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1523\/JNEUROSCI.2712-13.2014","article-title":"Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies","volume":"34","author":"Skibinski","year":"2014","journal-title":"J. Neurosci."},{"key":"2021112216514588500_BCJ-2016-1078C48","doi-asserted-by":"publisher","first-page":"273ra215","DOI":"10.1126\/scitranslmed.aaa3634","article-title":"Effect of selective LRRK2 kinase inhibition on nonhuman primate lung","volume":"7","author":"Fuji","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"2021112216514588500_BCJ-2016-1078C49","doi-asserted-by":"publisher","first-page":"33897","DOI":"10.1038\/srep33897","article-title":"Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation","volume":"6","author":"Lobbestael","year":"2016","journal-title":"Sci. Rep."},{"key":"2021112216514588500_BCJ-2016-1078C50","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1146\/annurev.pharmtox.40.1.617","article-title":"14-3-3 proteins: structure, function, and regulation","volume":"40","author":"Fu","year":"2000","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2021112216514588500_BCJ-2016-1078C51","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.tibs.2014.09.003","article-title":"Ultrasensitivity part II: multisite phosphorylation, stoichiometric inhibitors, and positive feedback","volume":"39","author":"Ferrel","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"2021112216514588500_BCJ-2016-1078C52","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.molcel.2006.12.017","article-title":"Structure of a 14-3-3 coordinated hexamer of the plant plasma membrane H+-ATPase by combining X-?ray crystallography and electron cryomicroscopy","volume":"25","author":"Ottmann","year":"2007","journal-title":"Mol. Cell"},{"key":"2021112216514588500_BCJ-2016-1078C53","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.chembiol.2013.03.015","article-title":"A semisynthetic fusicoccane stabilizes a protein\u2013protein interaction and enhances the expression of K+ channels at the cell surface","volume":"20","author":"Anders","year":"2013","journal-title":"Chem. Biol."},{"key":"2021112216514588500_BCJ-2016-1078C54","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/564534","article-title":"Neuroprotective function of 14-3-3 proteins in neurodegeneration","volume":"2013","author":"Shimada","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"2021112216514588500_BCJ-2016-1078C55","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fnagi.2015.00248","article-title":"Parkin regulation and neurodegenerative disorders","volume":"7","author":"Zhang","year":"2015","journal-title":"Front. Aging. Neurosci."},{"key":"2021112216514588500_BCJ-2016-1078C56","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/sj.emboj.7600774","article-title":"14-3-3\u03b7 is a novel regulator of Parkin ubiquitin ligase","volume":"25","author":"Sato","year":"2006","journal-title":"EMBO J."},{"key":"2021112216514588500_BCJ-2016-1078C57","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.1093\/hmg\/ddu275","article-title":"The chaperone-like protein 14-3-3\u03b7 interacts with human \u03b1-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing \u03b1-synuclein cellular toxicity","volume":"23","author":"Plotegher","year":"2014","journal-title":"Hum. Mol. Genet."}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/474\/7\/1273\/690564\/bcj-2016-1078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/474\/7\/1273\/690564\/bcj-2016-1078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T23:36:40Z","timestamp":1637624200000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/474\/7\/1273\/49734\/Structural-interface-between-LRRK2-and-14-3-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,23]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,4,1]]}},"URL":"https:\/\/doi.org\/10.1042\/bcj20161078","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,23]]}}}